AKT1 and endometrial cancer: In addition to the patient with endometrial cancer who met the CBR definition of SD (>6 months), a second patient with AKT1 E17K mutant endometrioid endometrial carcinoma had target lesion reduction (−19%) and remained on study for 6 cycles with SD.